Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Benzinga Newsdesk www.benzinga.com Neutral 78.8%

Neg 0% Neu 78.8% Pos 0%

Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.